Trial Profile
The ELTION Study - A Multicenter Open-label Interventional Study of Eltrombopag in Patients With Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Pancytopenia
- Focus Therapeutic Use
- Acronyms ELTION
- Sponsors Novartis Pharmaceuticals
- 17 Jun 2022 Results assessing efficacy and safety of eltrombopag in patients with post-allogenic hematopoietic stem cell transplant poor graft function, presented at the 27th Congress of the European Haematology Association.
- 11 Jan 2021 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Planned primary completion date changed from 30 Sep 2020 to 27 Nov 2020.